(DXCM) DexCom - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 24.267m USD | Total Return: 8.4% in 12m

Continuous Glucose Monitor, Sensor, Transmitter, Receiver
Total Rating 50
Safety 93
Buy Signal 0.11
Medical Devices
Industry Rotation: -4.7
Market Cap: 24.3B
Avg Turnover: 251M USD
ATR: 3.32%
Peers RS (IBD): 45.9
Risk 5d forecast
Volatility45.0%
Rel. Tail Risk-22.3%
Reward TTM
Sharpe Ratio0.27
Alpha-17.57
Character TTM
Beta0.750
Beta Downside0.067
Drawdowns 3y
Max DD60.95%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of DXCM over the last years for every Quarter: "2021-03": 0.08, "2021-06": 0.19, "2021-09": 0.22, "2021-12": 0.17, "2022-03": 0.08, "2022-06": 0.17, "2022-09": 0.28, "2022-12": 0.34, "2023-03": 0.17, "2023-06": 0.34, "2023-09": 0.5, "2023-12": 0.5, "2024-03": 0.32, "2024-06": 0.43, "2024-09": 0.45, "2024-12": 0.38, "2025-03": 0.32, "2025-06": 0.48, "2025-09": 0.61, "2025-12": 0.68, "2026-03": 0,
EPS CAGR: -37.20%
EPS Trend: 29.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of DXCM over the last years for every Quarter: 2021-03: 505, 2021-06: 595.1, 2021-09: 650.2, 2021-12: 698.2, 2022-03: 628.8, 2022-06: 696.2, 2022-09: 769.6, 2022-12: 815.2, 2023-03: 741.5, 2023-06: 871.3, 2023-09: 975, 2023-12: 1034.5, 2024-03: 921, 2024-06: 1004.3, 2024-09: 994.2, 2024-12: 1113.5, 2025-03: 1036, 2025-06: 1157.1, 2025-09: 1209.3, 2025-12: 1259.6, 2026-03: null,
Rev. CAGR: 20.35%
Rev. Trend: 95.1%
Last SUE: 0.34
Qual. Beats: 0

Warnings

Choppy

Tailwinds

No distinct edge detected

Description: DXCM DexCom

DexCom, Inc. (NASDAQ: DXCM) designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health, selling products such as the G7, G6, ONE+, and Stelo directly to endocrinologists, physicians, and diabetes educators. Founded in 1999 and headquartered in San Diego, the company operates globally across the health-care equipment sub-industry.

In the most recent quarter (Q2 2024), DexCom reported revenue of $1.13 billion, a 12% year-over-year increase driven by strong adoption of the G7 system and expanding reimbursement coverage in Europe and the United States. The CGM market is projected to grow at a CAGR of ~10% through 2028, with DexCom holding roughly 35% market share, second only to its main competitor. Additionally, the company’s operating margin improved to 22% as cost efficiencies from the newer G7 platform offset rising R&D spend.

For a deeper dive into the valuation metrics and competitive landscape, consider reviewing the analysis on ValueRay.

Headlines to Watch Out For
  • CGM system adoption drives revenue growth
  • Regulatory approvals expand market access for new devices
  • Reimbursement policies impact product affordability and sales
  • Competition from alternative glucose monitoring solutions affects market share
Piotroski VR‑10 (Strict) 8.5
Net Income: 836.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.17 > 0.02 and ΔFCF/TA 7.26 > 1.0
NWC/Revenue: 40.56% < 20% (prev 33.95%; Δ 6.60% < -1%)
CFO/TA 0.23 > 3% & CFO 1.44b > Net Income 836.3m
Net Debt (-609.0m) to EBITDA (1.34b): -0.46 < 3
Current Ratio: 1.88 > 1.5 & < 3
Outstanding Shares: last quarter (398.9m) vs 12m ago -1.92% < -2%
Gross Margin: 60.10% > 18% (prev 0.60%; Δ 5.95k% > 0.5%)
Asset Turnover: 72.71% > 50% (prev 62.19%; Δ 10.51% > 0%)
Interest Coverage Ratio: 59.28 > 6 (EBITDA TTM 1.34b / Interest Expense TTM 18.3m)
Altman Z'' 5.09
A: 0.30 (Total Current Assets 4.03b - Total Current Liabilities 2.14b) / Total Assets 6.34b
B: 0.38 (Retained Earnings 2.43b / Total Assets 6.34b)
C: 0.17 (EBIT TTM 1.08b / Avg Total Assets 6.41b)
D: 0.71 (Book Value of Equity 2.55b / Total Liabilities 3.59b)
Altman-Z'' Score: 5.09 = AAA
Beneish M -3.01
DSRI: 1.08 (Receivables 1.29b/1.03b, Revenue 4.66b/4.03b)
GMI: 1.01 (GM 60.10% / 60.46%)
AQI: 0.88 (AQ_t 0.11 / AQ_t-1 0.12)
SGI: 1.16 (Revenue 4.66b / 4.03b)
TATA: -0.10 (NI 836.3m - CFO 1.44b) / TA 6.34b)
Beneish M-Score: -3.01 (Cap -4..+1) = AA
What is the price of DXCM shares? As of April 09, 2026, the stock is trading at USD 65.80 with a total of 2,807,911 shares traded.
Over the past week, the price has changed by +5.50%, over one month by -4.28%, over three months by -3.84% and over the past year by +8.42%.
Is DXCM a buy, sell or hold? DexCom has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy DXCM.
  • StrongBuy: 17
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the DXCM price?
Analysts Target Price 87.1 32.4%
DexCom (DXCM) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 29.7703
P/E Forward = 24.9377
P/S = 5.2052
P/B = 8.7204
P/EG = 1.359
Revenue TTM = 4.66b USD
EBIT TTM = 1.08b USD
EBITDA TTM = 1.34b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 21.6m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -609.0m USD (recalculated: Debt 1.39b - CCE 2.00b)
Enterprise Value = 23.66b USD (24.27b + Debt 1.39b - CCE 2.00b)
Interest Coverage Ratio = 59.28 (Ebit TTM 1.08b / Interest Expense TTM 18.3m)
EV/FCF = 21.96x (Enterprise Value 23.66b / FCF TTM 1.08b)
FCF Yield = 4.55% (FCF TTM 1.08b / Enterprise Value 23.66b)
FCF Margin = 23.11% (FCF TTM 1.08b / Revenue TTM 4.66b)
Net Margin = 17.94% (Net Income TTM 836.3m / Revenue TTM 4.66b)
Gross Margin = 60.10% ((Revenue TTM 4.66b - Cost of Revenue TTM 1.86b) / Revenue TTM)
Gross Margin QoQ = 62.93% (prev 60.48%)
Tobins Q-Ratio = 3.73 (Enterprise Value 23.66b / Total Assets 6.34b)
Interest Expense / Debt = 0.30% (Interest Expense 4.20m / Debt 1.39b)
Taxrate = 21.54% (73.4m / 340.7m)
NOPAT = 851.1m (EBIT 1.08b * (1 - 21.54%))
Current Ratio = 1.88 (Total Current Assets 4.03b / Total Current Liabilities 2.14b)
Debt / Equity = 0.51 (Debt 1.39b / totalStockholderEquity, last quarter 2.75b)
Debt / EBITDA = -0.46 (Net Debt -609.0m / EBITDA 1.34b)
Debt / FCF = -0.57 (Net Debt -609.0m / FCF TTM 1.08b)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.04% (Net Income 836.3m / Total Assets 6.34b)
RoE = 32.44% (Net Income TTM 836.3m / Total Stockholder Equity 2.58b)
RoCE = 28.41% (EBIT 1.08b / Capital Employed (Equity 2.58b + L.T.Debt 1.24b))
RoIC = 18.02% (NOPAT 851.1m / Invested Capital 4.72b)
WACC = 8.17% (E(24.27b)/V(25.66b) * Re(8.62%) + D(1.39b)/V(25.66b) * Rd(0.30%) * (1-Tc(0.22)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.07%
[DCF] Terminal Value 81.05% ; FCFF base≈898.6m ; Y1≈1.11b ; Y5≈1.89b
[DCF] Fair Price = 83.23 (EV 31.42b - Net Debt -609.0m = Equity 32.03b / Shares 384.9m; r=8.17% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 29.40 | EPS CAGR: -37.20% | SUE: -4.0 | # QB: 0
Revenue Correlation: 95.09 | Revenue CAGR: 20.35% | SUE: 0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.60 | Chg7d=+0.002 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=20
EPS current Year (2026-12-31): EPS=2.49 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=-2 | Growth EPS=+19.4% | Growth Revenue=+12.2%
EPS next Year (2027-12-31): EPS=2.99 | Chg7d=+0.003 | Chg30d=+0.002 | Revisions Net=-2 | Growth EPS=+19.9% | Growth Revenue=+12.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 8.6% - Earnings Yield 3.4%)
[Growth] Growth Spread = +6.9% (Analyst 12.1% - Implied 5.3%)
External Resources
Dataroma Stockcircle